Hanmi Science Subsidiary Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin in USD 237.5 Million Deal

Bitget2026/10/29 22:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hanmi Science subsidiary Hanmi Pharmaceutical signed a USD 237.5 million Fabry disease licensing deal with BioMarin on October 29, 2026.
The agreement includes USD 35 million upfront, USD 202.5 million in milestone payments, and royalties based on annual net sales.
BioMarin receives exclusive worldwide rights to LA-GLA; Hanmi Pharmaceutical and GC retain approval and commercialization rights in South Korea.
The long-acting enzyme replacement therapy, also called HM15421, is undergoing Phase 1/2 trials domestically and overseas, with GC jointly developing it.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800021), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hanmi Science Subsidiary Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin in USD 237.5 Million Deal

You may also like

Crypto prices